Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.

Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.

June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.

Sura-vec is a 1-time investigational gene therapy designed to deliver sustained treatment in wet AMD, diabetic retinopathy and other chronic retinal conditions.

The trial over-enrolled and finished approximately 4 months ahead of initial projections, with 52-week topline data now expected in the second half of 2027.

Ultra-widefield imaging reveals early retinal risk in pediatric patients.

Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care—and where voice-command wearables fit alongside traditional rehabilitation tools.

Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.